Therapeutic cancer vaccines

Area of Science:

• Immunology
• Oncology
• Vaccinology

Background:

• Therapeutic cancer vaccines have demonstrated clinical benefit, particularly in prolonging survival for cancer patients.
• Previous successes include regression of premalignant lesions caused by the human papillomavirus (HPV).
• However, cancer eradication remains a challenge due to suboptimal vaccine design and an immunosuppressive tumor microenvironment.

Purpose of the Study:

• To explore strategies for enhancing the efficacy of therapeutic cancer vaccines.
• To identify optimal vaccine designs, antigen choices, and methods to overcome tumor-induced immunosuppression.

Main Methods:

• Effective vaccine platforms include DNA, RNA, and synthetic long peptides.
• Antigen selection focuses on mutant sequences, cancer-testis antigens, and viral antigens.
• Immunosuppressive microenvironments can be modulated by chemotherapeutics, radiation, indoleamine 2,3-dioxygenase (IDO) inhibitors, T cell checkpoint inhibitors, TNF receptor agonists, and cytokine inhibitors.

Main Results:

• Effective vaccines concentrate antigen to human leukocyte antigen (HLA) class I and II molecules on dendritic cells (DCs).
• This promotes robust CD4 and CD8 T cell responses.
• Combination therapies targeting the tumor microenvironment enhance vaccine potential.

Conclusions:

• Optimized vaccine design and strategies to counteract tumor immunosuppression are crucial for improving therapeutic cancer vaccine efficacy.
• The combination of specific therapeutic vaccination with immunomodulation presents a promising approach for future cancer therapies.